Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development 105

Drug Development Communication Immunity Immunization 105

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development 98

Drug Development Communication Immunity Immunization 98

Pharmaceutical Technology

MARCH 24, 2023

In light of World TB day on March 24, the field hopes to overcome some major barriers to the drug development landscape. Unfortunately, lack of funding and resources remain an obstacle within the TB field for developing new vaccines. The BCG vaccine is a live-attenuated virus vaccine.

Vaccines 64

Vaccines Health and Personal Care Stores Immunity Immunization 64

Pharmaceutical Technology

MARCH 9, 2023

UCB4594 targets the immune checkpoint, human leukocyte antigen G, which is also called HLA-G. Under the partnership, the Centre for Drug Development of Cancer Research UK will appoint the chief clinical and scientific investigators.

Communication 52

Communication Immunity Immunization Drug Development 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Biocytogen’s independently developed bispecific antibody, YH008, exerts antagonistic and agonistic activities. It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies.

Immunity 52

Immunity Immunization Communication Drug Development 52

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines 52

Vaccines Communication Immunity Immunization 52